quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·14d
PRRelease
Bristol-Myers Squibb Company logo

Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

BMY· Bristol-Myers Squibb Company
Health Care
Original source

Companies

  • BMY
    Bristol-Myers Squibb Company
    Health Care

Recent analyst ratings

  • Feb 25UpdateRBC Capital Mkts$60.00
  • Feb 20UpdateBarclays$75.00
  • Jan 7UpdateUBS$65.00
  • Dec 15UpdateBofA Securities$61.00
  • Dec 12UpdateGuggenheim$62.00
  • Nov 13UpdateScotiabank$45.00

Related

  • PR16h
    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
  • PR2d
    Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
  • PR3d
    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
  • SEC6d
    SEC Form DEFA14A filed by Bristol-Myers Squibb Company
  • PR8d
    Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases
  • INSIDER21d
    SEC Form 4 filed by Shanahan Karin
  • INSIDER21d
    SEC Form 4 filed by Elkins David V
  • INSIDER21d
    SEC Form 4 filed by Yale Phyllis R
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022